1. Home
  2. BCG vs LGVN Comparison

BCG vs LGVN Comparison

Compare BCG & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

HOLD

Current Price

$1.56

Market Cap

24.4M

Sector

N/A

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.75

Market Cap

25.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCG
LGVN
Founded
2016
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.4M
25.9M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
BCG
LGVN
Price
$1.56
$0.75
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
45.6K
328.1K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
112.50
50.76
EPS
0.08
N/A
Revenue
$187,144,000.00
$709,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.81
P/E Ratio
$17.22
N/A
Revenue Growth
10.80
N/A
52 Week Low
$1.26
$0.48
52 Week High
$3.44
$1.23

Technical Indicators

Market Signals
Indicator
BCG
LGVN
Relative Strength Index (RSI) 57.94 56.26
Support Level $1.43 $0.61
Resistance Level $1.61 $0.87
Average True Range (ATR) 0.10 0.06
MACD 0.02 0.01
Stochastic Oscillator 75.00 75.46

Price Performance

Historical Comparison
BCG
LGVN

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: